Want to join the conversation?
$JNJ 2Q15 Call-Sandra, Group Chairman: Diabetes is the fourth largest healthcare category in the world. Globally, therapies and devices market is growing at 5%; & 50% of patients with diabetes are unfortunately undiagnosed or not in control. In the blood glucose monitoring, we hold the number one value and volume positions in our nine top markets.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.